Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.47
+0.91 (4.03%)
At close: Feb 6, 2026, 4:00 PM EST
23.49
+0.02 (0.09%)
After-hours: Feb 6, 2026, 4:10 PM EST
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,431,545
Profits / Employee
$63,361
Market Cap
2.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 710 | 4 | 0.57% | 705 | 5 |
| Dec 31, 2023 | 706 | -61 | -7.95% | 702 | 4 |
| Dec 31, 2022 | 767 | 291 | 61.13% | 767 | 0 |
| Dec 31, 2021 | 476 | 102 | 27.27% | 476 | 0 |
| Sep 30, 2021 | 486 | 136 | 38.86% | 486 | 0 |
| Jun 30, 2021 | 445 | 148 | 49.83% | 445 | 0 |
| Mar 31, 2021 | 391 | 125 | 46.99% | 391 | 0 |
| Dec 31, 2020 | 374 | 139 | 59.15% | 374 | 0 |
| Sep 30, 2020 | 350 | 149 | 74.13% | 350 | 0 |
| Jun 30, 2020 | 297 | 175 | 143.44% | 297 | 0 |
| Mar 31, 2020 | 266 | 186 | 232.50% | 266 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Xenon Pharmaceuticals | 327 |
| Dyne Therapeutics | 240 |
| Vera Therapeutics | 224 |
| Catalyst Pharmaceuticals | 181 |
| Immunome | 168 |
| Viridian Therapeutics | 143 |
| Disc Medicine | 142 |
APLS News
- 11 days ago - TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - PRNewsWire
- 17 days ago - Apellis Valuation Ignores Empaveli Potential, Says Analyst - Benzinga
- 26 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 26 days ago - Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha